Content about Neurological disorders

January 11, 2011

Bayer HealthCare Pharmaceuticals sought to reassure healthcare professionals and their patients that a recall of alcohol prep pads distributed with its multiple sclerosis drug did not affect the drug itself.

WAYNE, N.J. — Bayer HealthCare Pharmaceuticals sought to reassure healthcare professionals and their patients that a recall of alcohol prep pads distributed with its multiple sclerosis drug did not affect the drug itself.

The drug maker’s MS treatment Betaseron (interferon beta-1b) is distributed with prep pads made by Triad Group, which recently staged a recall of prep products due to potential contamination with Bacillus cereus bacteria, which would lead to life-threatening infections.

December 17, 2010

Prestige Brands Holdings on Thursday announced that it has entered into a definitive agreement to acquire the assets associated with the Dramamine business in the United States from McNeil Consumer Healthcare for $76 million in cash.

IRVINGTON, N.Y. — Prestige Brands Holdings on Thursday announced that it has entered into a definitive agreement to acquire the assets associated with the Dramamine business in the United States from McNeil Consumer Healthcare for $76 million in cash.

“The company expects to quickly and smoothly integrate Dramamine into the Prestige portfolio and drive growth through enhanced brand support,” stated Matthew Mannelly, Prestige Brands CEO.

November 7, 2010

Eli Lilly's acquisition of a leader in molecular imaging development could boost its Alzheimer's disease...

INDIANAPOLIS and PHILADELPHIA Eli Lilly's acquisition of a leader in molecular imaging development could boost its Alzheimer's disease drug pipeline.

November 4, 2010

The Food and Drug Administration has approved a new usage for a drug used to...

INDIANAPOLIS The Food and Drug Administration has approved a new usage for a drug used to treat depression and pain.

Eli Lilly said Thursday that the FDA had approved Cymbalta (duloxetine hydrochloride) for treating chronic musculoskeletal pain. This is the fifth indication for which the agency has approved Cymbalta, after major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain and fibromyalgia, Lilly said.

November 3, 2010

Nearly 100 drugs are in development for treating Alzheimer’s disease, according to a new report...

WASHINGTON Nearly 100 drugs are in development for treating Alzheimer’s disease, according to a new report by the main lobby for the pharmaceutical industry.

 

The Pharmaceutical Research and Manufacturers of America said 98 medicines for dementia, mostly Alzheimer’s, were in clinical trials or under review by the Food and Drug Administration.

 

 

October 17, 2010

A popular beauty treatment has won approval as a medical treatment as well....

SILVER SPRING, Md. A popular beauty treatment has won approval as a medical treatment as well.

 

The Food and Drug Administration announced Friday the approval of Allergan’s Botox (onabotulinumtoxinA) for preventing headaches in adult patients with chronic migraine.

 

 

October 17, 2010

A company that develops drugs for pain is hoping to get approval of one of...

SAN MATEO, Calif. A company that develops drugs for pain is hoping to get approval of one of its drugs for a pain condition associated with HIV.

October 3, 2010

Privately owned drug-development company ProteoTech will work with a Chinese company to develop a drug...

KIRKLAND, Wash. Privately owned drug-development company ProteoTech will work with a Chinese company to develop a drug to treat Alzheimer’s disease, ProteoTech said Monday.

 

September 21, 2010

The Food and Drug Administration has approved a drug for reducing relapses in patients with...

SILVER SPRING, Md. The Food and Drug Administration has approved a drug for reducing relapses in patients with multiple sclerosis.

 

The FDA announced Wednesday the approval of Swiss drug maker Novartis’ Gilenia (fingolimod) capsules, saying it was the first oral drug that can slow the progression of disability in patients with MS and offered an alternative to injected drugs.

 

 

Around 400,000 people in the United States and 2.1 million worldwide have MS, according to the National Multiple Sclerosis Society.

September 16, 2010

The Food and Drug Administration has accepted for review a regulatory approval application for a...

WOODCLIFF LAKE, N.J. The Food and Drug Administration has accepted for review a regulatory approval application for a patch made by Eisai to treat Alzheimer’s disease, the drug maker said Friday.

 

The agency will review a patch formulation of Aricept (donepezil hydrochloride), a weekly patch for treating mild, moderate and severe stages of the disease. The drug already is available in tablet form.

 

 

August 31, 2010

Pfizer announced Wednesday that it will acquire a privately held drug discovery and clinical development...

August 26, 2010

Topical BioMedics on Thursday announced that its Topricin pain relief and healing cream has been...

RHINEBECK, N.Y. Topical BioMedics on Thursday announced that its Topricin pain relief and healing cream has been awarded a patent as a treatment of pain associated with fibromyalgia. A Food and Drug Administration-regulated topical biomedicine, Topricin was introduced by the company in 1994, the company stated.

 

August 16, 2010

Lackluster results have prompted Eli Lilly to stop two late-stage clinical trials of a drug...

August 16, 2010

US WorldMeds has acquired Solstice Neurosciences for $35.7 million, US WorldMeds said....

August 2, 2010

Reed's, the maker of a line of sodas popular in natural food stores, on Tuesday...

LOS ANGELES Reed's, the maker of a line of sodas popular in natural food stores, on Tuesday announced that Publix will begin carrying Reed's natural ginger nausea relief, a ginger-based remedy for nausea and motion sickness, in the over-the-counter remedy aisle in all Publix locations.

 

"This is a terrific fit for both Reed's and Publix and we are excited to introduce Reed's natural ginger nausea relief into all Publix supermarket locations in the Southeast and expand our distribution," stated Chris Reed, chairman and CEO of Reed's.

 

August 1, 2010

The Food and Drug Administration has approved a treatment for muscle spasms and twitches....

GREENSBORO, N.C. The Food and Drug Administration has approved a treatment for muscle spasms and twitches.

 

August 1, 2010

The Food and Drug Administration has approved a generic injected drug made by Sagent Pharmaceuticals...

SCHAUMBURG, Ill. The Food and Drug Administration has approved a generic injected drug made by Sagent Pharmaceuticals for treating migraine attacks, Sagent said Monday.

 

The FDA approved Sagent’s sumatriptan succinate injection in the 6 mg per 0.5 milliliter strength. The drug is used to treat acute migraine attacks and cluster headache episodes.

 

 

Sumatriptan is a generic version of GlaxoSmithKline’s Imitrex. Injectable sumatriptan had $22 million in sales in 2009, according to IMS Health.

July 19, 2010

Drug maker Pfizer is suspending some clinical studies of a biotech drug for treating pain...

July 19, 2010

More than 300 medications for treating mental disorders are in development, according to a new...

WASHINGTON More than 300 medications for treating mental disorders are in development, according to a new report by a pharmaceutical industry lobbying group.

 

July 13, 2010

The market for multiple sclerosis drugs, long dominated by biologics and injectables, soon could see...

July 11, 2010

Sandoz has launched a generic drug for treating migraine headaches, the generics arm of Swiss...

PRINCETON, N.J. Sandoz has launched a generic drug for treating migraine headaches, the generics arm of Swiss drug maker Novartis said Monday.

 

Sandoz launched naratriptan hydrochloride tablets in the 2.5-mg strength, a generic version of GlaxoSmithKline’s Amerge. The tablets are used for treating acute migraine attacks in adults with or without visual disturbances that occur before the onset of the headache, also known as aura. Studies have indicated that around 12% of Americans have migraine attacks.

 

 

June 14, 2010

The Food and Drug Administration has agreed to speed up the review of a Genzyme...

June 13, 2010

An advisory committee of the Food and Drug Administration unanimously recommended approval for an investigational...

June 7, 2010

Nautilus Neurosciences has launched a new treatment for migraines, the drug maker said Tuesday....

May 23, 2010

The Food and Drug Administration has granted special designation to encourage the development of a...